Evidence map›Paper›PMID 27666868›Full record

ArticleScientific reports2016

Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC).

Carlo Garufi, Elisa Giacomini, Angela Torsello, Isabella Sperduti, Elisa Melucci, Marcella Mottolese, Massimo Zeuli, Giuseppe Maria Ettorre, Teresa Ricciardi, Francesco Cognetti and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Sexual Dimorphism in Colon Cancer.Frontiers in oncology · 2020
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Carlo GarufiDivision of Medical Oncology, Spirito Santo Hospital Pescara, Italy.
Elisa GiacominiDept. of Biomolecular Sciences (DiSB) University of Urbino "Carlo Bo", Urbino, Italy.
Angela TorselloDivision of Medical Oncology Azienda Ospedaliera San Giovanni Addolorata Hospital, Rome, Italy.
Isabella SperdutiBiostatistic Unit, Regina Elena National Cancer Institute Rome, Italy.
Elisa MelucciPathology Department Regina Elena National Cancer Institute Rome, Italy.
Marcella MottolesePathology Department Regina Elena National Cancer Institute Rome, Italy.
Massimo ZeuliDivision of Medical Oncology Regina Elena National Cancer Institute Rome, Italy.
Giuseppe Maria EttorreGeneral Surgery and Transplantation Unit San Camillo Hospital Rome, Italy.
Teresa RicciardiDept. of Biomolecular Sciences (DiSB) University of Urbino "Carlo Bo", Urbino, Italy.
Francesco CognettiDivision of Medical Oncology Regina Elena National Cancer Institute Rome, Italy.
Mauro MagnaniDept. of Biomolecular Sciences (DiSB) University of Urbino "Carlo Bo", Urbino, Italy.
Annamaria RuzzoDept. of Biomolecular Sciences (DiSB) University of Urbino "Carlo Bo", Urbino, Italy.
University of Urbino · ITNational Cancer Institute · MYAzienda Ospedaliera San Giovanni Addolorata · ITIRCCS San Camillo Hospital · ITOspedale di Santo Spirito · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The circadian system is composed of a set of clock-genes including PERIOD, CLOCK, BMAL1 and CRY. Disrupting this system promotes cancer development and progression. The expression levels of miR-206, miR-219, miR-192, miR-194 and miR-132 regulating clock-genes and three functional polymorphisms rs11133373 C/G, rs1801260 T/C, rs11133391 T/C in CLOCK sequence were associated with the survival of 83 mCRC patients (50 males and 33 females). Longer overall survival (OS) was observed in women compared to men, 50 versus 31 months. This difference was associated with rs11133373 C/C genotype (p = 0.01), rs1801260 T/C+C/C genotype (p = 0.06) and rs11133391 T/T genotype (p = 0.06). Moreover women expressing high levels (H) of miR-192 (p = 0.03), miR-206 (p = 0.003), miR-194 (p = 0.02) and miR-219 (p = 0.002) had a longer OS compared to men. In women longer OS was reinforced by the simultaneous presence of two or more H-miR, 58 months versus 15 months (p = 0.0008); in this group of women an OS of 87 months was reached with the additional presence of rs11133391T/T genotype (p = 0.02). In this study we identified a subgroup of female patients who seems to have a better prognosis. Personalized medicine should prospectively take into account both genetic and gender differences.

Identifiers

PMID27666868
PMCPMC5036027
OpenAlexW2527266411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.